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Abstract: The aim of this study was to examine the effect of estrogen on fibrinogen clotting time in rabbit model experimentally.
The study was performed on 14 white New Zealand race female prepubertary rabbits at two months old weighing meanly 1.4±0.3
kg. Blood samples was taken from ear veins of the rabbits and first fibrinogen clotting time levels were measured to obtain control
values. Next day, female sex hormone preparate estradiol valerinate at a dose of 0.3 mg/kg were injected to the rabbits IM. In their
examinations made on 10th day of injection, they were evaluated as in oestrus and under the maximal effects of estrogen, and their
blood samples were taken again to measure their fibrinogen clotting time levels. Fibrinogen clotting time levels were determined
from blood samples taken before and after female sex hormone administration. Samples taken from ear veins of the rabbits were
used for measurement of fibrinogen clotting time. In the study, fibrinogen clotting time values were found meanly 18.13±1.00 sec.
from blood samples taken before estrogen injection versus 18.87±0.61 sec. from blood samples after 10 days of estrogen injection. In statistical assessment performed, there were not statistically significant differences (t=0.94, p>0.05) between fibrinogen
clotting time values before and after estrogen administration. Our data revealed that estrogen administration caused a silghtly but
insignificantly increase in fibrinogen clotting time values in the rabbits.
Key Words: Estrogen, fibrinogen clotting time, rabbit.

Tavşanlarda Östrojenin Fibrinojen Pıhtılaşma Zamanına Etkisi
Özet: Bu çalışmanın amacı, deneysel olarak tavşan modelinde östrojenin fibrinojen pıhtılaşma zamanına (FPZ) etkisini araştırmaktı.
Çalışma, ortalama olarak 1.4±0.3 kg ağırlığına sahip prepuberter dönemdeki 2 aylık beyaz Yeni Zellanda ırkı 14 tavşan üzerinde
gerçekleştirildi. Tavşanların kulak venlerinden kan örnekleri alındı ve kontrol değerlerini elde etmek için ilk FPZ düzeyleri ölçüldü.
Ertesi gün, tavşanlara dişi seks hormon preparatı östradiol valerinat 0.3 mg/kg dozda kas içine injekte edildi. Tavşanların injeksiyonunun 10. gününde yapılan muayenesinde, tavşanlar östrusta ve östrojenin maksimal etkisi altında olarak değerlendirildi ve FPZ
düzeylerini ölçmek üzere tekrar kanları alındı. FPZ düzeyleri dişi seks hormon preparatı verilmeden önce ve sonra alınan kan
örneklerinden tespit edildi. Çalışma, FPZ düzeyleri östrojen injeksiyonundan önceki kan örneklerinde ortalama olarak 18.13±1.0 sn
olarak bulunurken, östrojen injeksiyonunun 10. gününde alınan kan örneklerinde 18.87±0.61 sn olarak bulundu. Yapılan istatistiksel değerlendirmede, östrojen verilmesi öncesi ve sonnrası FPZ düzeyleri arasında anlamlı farklılık (t=0.94, p>0.05) yoktu. Bulgularımız tavşanlara östrojen verilmesinin FPZ değerlerinde hafifçe fakat anlamlı olmayan bir artışa neden olduğunu gösterdi.
Anahtar Sözcükler: Östrojen, fibrinojen pıhtılaşma zamanı, tavşan.

Introduction
Human fibrinogen is a glucoprotein weighing
340.000 daltons. It is composed of three pairs of
peptide chains connected by disulfide bridges to form
a molecule composed of symmetrical halves. Fibrinogen
as a blood protein takes place in a variety of physio-

logical and pathophysiological events. It is among the
most important factors determining especially clotting
time of the blood (1).
For the measurement of plasma fibrinogen level
(PFL), the commonest laboratory method is to
measure fibrinogen clotting time (FCT) by coagulome-
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ter. According to our knowledge today, obtained FCT
values by coagulometer are converted to PFL values by
use of transformation tables. According to these tables
increasing PFL values cause decreasing FCT values. In
the later literature, the FCT values are preferred
instead of PFL values (2). For this reason, in this
study, the FCT values were preferred instead of PFL.
According to our knowledge today, it is known to
be some differences between male and female PFLs.
However, it is understood from basic books and literature research that the factors determining normal PFL
or FCT are not known clearly. In addition, we know
of no experimental study that have examined relationship between male and female sex hormones and
plasma fibrinojen levels in animals. In this purpose, we
investigated the effect of female sex hormones on FCT
and consequently on PFL in rabbit model.
Material and Method
Trial animals and trial procedure
In this study, 14 white New Zealand race female
prepubertary rabbits at two months old weighing
meanly 1.4±0.3 kg were used. The rabbits were
caged in laboratory animals section of Yüzüncü Yıl University (YYU) Medical School, providing medium temperature of 10±4ºC during experiment. The rabbits
were fed with rabbit fodder prepared by Animal feeding section of YYU Veterinay Faculty, in addition to
other foods such as cabbage, lettuce and water adlibutum during trial.
After the rabbits were bought and brought to our
section, they were waited for adaptations to their new
place for one week period, then blood samples were
taken and their clotting time levels were measured so
that they were taken as control. Next day, female hormone preparate estradiol valerinate at a dose of 0.3
mg/kg were injected to the rabbits IM. The rabbits
were observed after the injection, In their examinations made on 10th day of injection, they were evaluated as in oestrus and under the maximal effects of
estrogen, then their blood samples were taken again
so as to measure their fibrinogen clotting time values.

EDTA within. FCTs were measured by coagulamater
(Coulter IL MCL2) using ready kits (diagnostica-fibri
prest automate kit). The results were expressed as
seconds (3).
Statistical assessments
Statistical analysis was done by “paired, two tailed
student t” test using the Microsoft excel 7.0 computer
program. The values of p<0.05 were accepted as statistically significant. The values obtained were shown
as “mean ±SD”.
Results
In the study, FCT values were found meanly
18.13±1.00 sec. from blood samples taken before
estrogen injection versus 18.87±0.61 sec. from blood
samples after 10 days of estrogen injection. FCT values before and after 10 days of estrogen are shown
in Table and Figure. In statistical assessment performed, there were no statistically significant diffrences (t=0.94 p>0.05) between FCT values before
and after estrogen administration.
Discussion
Fibrinogen is essentially a glycoprotein and exists
within the plasma and platelets playing a role in blood
coagulation as a basic physiologic reaction. Fibronogen
is synthesized in liver parenchymal cells. Fibrinogen is
an acute phase reactant and plasma level may increase
as much as eight fold in response to inflammatory

Table.

Before estrogen
administration

Measurements of Fibrinogen clotting time levels
FCT levels were determined from blood samples
taken before and after female sex hormone administration. Samples taken from ear veins of the rabbits
were used for measurement of fibrinogen clotting
time. Blood samples were taken into tubes containing
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Fibrinogen clotting time values (sec) before and after 10
days of estrogen administration (n=14).

Mean
SD

18,1
17,4
16,9
18,5
18,9
15,8
18,4
17,6
17,4
19,2
19,4
19,1
18,5
18,7
18,13
1,009

Ten days after
estrogen
administration
19,6
19,8
18,7
17,9
18,8
19,6
18,6
18,8
19,3
17,7
19,1
18,5
19,2
18,7
18,87
0,61
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a significant increase in the luteal phase compared to
the follicular phase and midcycle. Fibrinogen showed a
positive correlation with progestoren effect (11).

20 -

Fibrinogen clotting time (sc)

19,5 -

In a study to investigate coagulation system activation following estrogen treatment in postmenopausal
women, significant increases in mean plasma PFL and
fibrinopeptid A levels were seen (12). In another study
to detect the effects of estrogen therapy and orchidectomy on coagulation in patients with prostatic cancer,
during long-term estrogen treatment were found to
have increased levels of factor VII, factor VIII-C and
fibrinogen (13).

19 18,5 -

*

18 17,5 17 16,5
Before

Figure.

After

Fibrinogen clotting time values before and after 10 days of
estrogen administration (n=14), (* t= 0.94, p>0.05)

challenge. The most important agents stimulating its
synhtesis are glucocorticoids and IL-6 released from
monocytes named as hepatocyte-stimulating factor
(4,5).
Fibrinogen degradation products and some endotoxins activate fibrinogen synthesis. Although the role of
hormones are not known clearly, it has been known
that insulin has negative effect on fibrinogen production. Chronic alcoholism and smoking increase the
fibrinogen synthesis (6,7,8).
It has been shown that fibrinogen is an important
risk factor in cardiovascular diseases. In ischemic
stroke patients, FCT is decreased and PFL is increased
(9).
In pregnancy, thyroid binding globulin and cortisol
binding globulin both increase, as do complement proteins and fibrinogen, the later resulting in a normally
high ESR, in which estrogen and progesterone rise
dramatically (10).
We know of no experimental study performed on
laboratory animals that have examined the relationship
between estrogen and FCT or PFL. But there is a
number of studies in this subject performed on
patients of different situation.
In a study performed to detect coagulation during
the normal menstrual cycle, antithrombin III and and
factor IV did not change; fibrinogen, however, showed

A clinical investigation was undertaken of the hemorrheologic effects of short-term administration of sex
hormones. Estrogens and progesterone singly or in
combination, were found to cause a rise in blood viscosity. Estrogens did so by raising hematocrit and plasma
fibrinogen, parameters are similiarly raised in other conditions such as pregnancy and surgery (14).
In studies to detect hemorrheological effect of triphasic oral contraceptives, fibrinogen was increased
either significantly or slighty (15,16,17).
As there are studies showing no significant difference in coagulation with estrogens in associated with
cyproteron acetate at twelve months (18), there are
investigations showing decreases in PFLs by estrogen
and/or progesterone. In a study to detect the possible
effect
on
coagulation
of
17-ß-oestradioldhydrogesterone therapy in postmenapausal women for
twelve months, fibrinogen was decreased slightly, but
significantly below the inital value (19). In another
study to investigate the effects of estrogen or estrogen/
progestin regimens on heart disease risk factor in postmenapausal women showed that estrogen alone or in
combination with a progestin improved lipoproteins and
lowered PFLs without detectable effects on postchallenge insulin or blood pressure (3).
In the present study, FCT values were found meanly
18.13±1.00 sec. from blood samples taken before
estrogen injection versus 18.87±0.621 sec. from blood
samples after 10 days of estrogen injection. There were
no statistically significant differences (t=0.94 p>0.05)
between FCT values before and after estrogen administration. As a result, our data revealed that estrogen
administration caused a slightly but insignificantly
increase in fibrinogen clotting time values (or decrease
plasma fibrinogen values) in the rabbits.
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